324769-06-4

Basic information

• Product Name: 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE
• Synonyms: 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE;tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3,3-diMethyl-4-oxo-, 1,1-diMethylethyl ester;1,1-Dimethylethyl 3,3-dimethyl-4-oxo-1-piperidinecarboxylate;1-tert-Butoxycarbonyl-3,3-dimethyl-4-piperidone;1-tert-Butyloxycarbonyl-3,3-dimethyl-4-piperidone;3,3-Dimethyl-4-oxo-1-piperidinecarboxylic acid tert-butyl ester;tert-butyl 3,3-diMethyl-4-oxopiperidine-1-carb
• CAS NO: 324769-06-4
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.31
• Mol File: 324769-06-4.mol

Chemical Properties

• Boiling Point: 303℃
• Flash Point: 137℃
• Appearance: /
• Density: 1.035
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.467
• Storage Temp.: 2-8°C
• PKA: -1.51±0.40(Predicted)
• CAS DataBase Reference: 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE(324769-06-4)
• EPA Substance Registry System: 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE(324769-06-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 324769-06-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE is used as a research chemical for the development of new pharmaceutical compounds. Its unique structure and functional groups make it a valuable intermediate in the synthesis of various drug candidates.
Used in Chemical Synthesis:
In the chemical synthesis industry, 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE is used as a key intermediate in the production of complex organic molecules. Its specific functional groups facilitate targeted reactions, contributing to the creation of specialized chemical products.
Used in Laboratory Settings:
Due to its specialized nature and the need for expert knowledge, 1-(TERT-BUTOXYCARBONYL)-3,3-DIMETHYL-4-OXOPIPERIDINE is used in laboratory settings for conducting advanced chemical research and experiments. Its application in these controlled environments ensures the safe and effective use of the compound for scientific discovery and innovation.

InChI:InChI=1/C12H21NO3/c1-11(2,3)16-10(15)13-7-6-9(14)12(4,5)8-13/h6-8H2,1-5H3

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 173186-91-9 N-benzyl-3,3-dimethylpiperidine-4-one 
• 150668-82-9 3,3-Dimethyl-piperidin-4-one 
• 563-80-4 3-methyl-butan-2-one 
• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 
• 324769-02-0 (rac)-1-Benzyl-3,3-dimethyl-piperidin-4-ol 
• 31648-35-8 1-benzyl-3,3-dimethyl-2,4-piperidinedione 

Downstream Products

• 570409-62-0 t-butyl 8,8-dimethyl-3-nitro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 
• 475085-56-4 4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1242241-51-5 (S,E)-tert-butyl 3,3-dimethyl-4-(1-phenylethylimino)piperidine-1-carboxylate 
• 264905-39-7 4-(N-ethylamino)-1-tert-butoxycarbonylpiperidine 
• 150668-82-9 3,3-Dimethyl-piperidin-4-one 
• 690660-21-0 4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol 
• 690660-22-1 (S)-4-(4-chlorophenyl)-3,3-dimethylpiperidin-4-ol 
• 946594-20-3 tert-butyl (R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1400580-24-6 C₂₀H₃₀N₂O₂ 
• 1242241-64-0 (S)-tert-butyl 3,3-dimethyl-4-((S)-1-phenylethylamino)-piperidine-1-carboxylate 
• 1357396-57-6 tert-butyl (R)-3,3-dimethyl-4-(((R)-1-phenylethyl)amino)piperidine-1-carboxylate 
• 1357600-60-2 C₁₂H₂₄N₂O₂ 
• 1357600-61-3 tert-butyl (R)-4-amino-3,3-dimethylpiperidine-1-carboxylate 
• 941815-63-0 C₂₁H₃₀N₄O₄S 

Relevant articles and documents

Protein Modification at Tyrosine with Iminoxyl Radicals

Post-translational modifications (PTMs) of proteins are a biological mechanism for reversibly controlling protein function. Synthetic protein modifications (SPMs) at specific canonical amino acids can mimic PTMs. However, reversible SPMs at hydrophobic amino acid residues in proteins are especially limited. Here, we report a tyrosine (Tyr)-selective SPM utilizing persistent iminoxyl radicals, which are readily generated from sterically hindered oximes via single-electron oxidation. The reactivity of iminoxyl radicals with Tyr was dependent on the steric and electronic demands of oximes; isopropyl methyl piperidinium oxime 1f formed stable adducts, whereas the reaction of tert-butyl methyl piperidinium oxime 1o was reversible. The difference in reversibility between 1f and 1o, differentiated only by one methyl group, is due to the stability of iminoxyl radicals, which is partly dictated by the bond dissociation energy of oxime O-H groups. The Tyr-selective modifications with 1f and 1o proceeded under physiologically relevant, mild conditions. Specifically, the stable Tyr-modification with 1f introduced functional small molecules, including an azobenzene photoswitch, to proteins. Moreover, masking critical Tyr residues by SPM with 1o, and subsequent deconjugation triggered by the treatment with a thiol, enabled on-demand control of protein functions. We applied this reversible Tyr modification with 1o to alter an enzymatic activity and the binding affinity of a monoclonal antibody with an antigen upon modification/deconjugation. The on-demand ON/OFF switch of protein functions through Tyr-selective and reversible covalent-bond formation will provide unique opportunities in biological research and therapeutics.

PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES AS KINASE JAK INHIBITORS

A compound or its acid addition salt of the general formula (I), wherein R1 represents phenyl substituted with one or two substituents selected from the group consisting of halogen and C1-C3 alkoxyl, or 6-membered heteroaryl with 1 or 2 nitroge

5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) in which the variables are as described herein.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The discovery of BMS-457, a potent and selective CCR1 antagonist

A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel pote

Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs w

ASYMMETRIC UREAS AND MEDICAL USES THEREOF

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I):

ASYMMETRIC UREAS AND MEDICAL USES THEREOF

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I).

Substituted Benzamide Compounds

Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.